成纤维细胞生长因子受体在尿路上皮癌中的研究进展。
Fibroblast growth factor receptors across urothelial carcinoma landscape.
机构信息
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Department of Urology, Weill Cornell Medical College, New York, USA.
出版信息
Curr Opin Urol. 2020 Jul;30(4):557-565. doi: 10.1097/MOU.0000000000000782.
PURPOSE OF REVIEW
Fibroblast growth factor receptor (FGFR) signalling, especially induced by FGFR3, is a crucial factor in the pathogenesis of urothelial carcinoma and was therefore extensively studied over the last decades. In this review, we summarize the most relevant findings of the past two years.
RECENT FINDINGS
Recent studies support the concept that FGFR3 mediates a pathway of urothelial carcinogenesis associated with low malignant potential. FGFR3 may represent a highly accurate biomarker for diagnosis and prediction of recurrence, progression or therapy response. The pan FGFR-inhibitor erdafitinib was recently approved for urothelial carcinoma, whereas several other FGFR-targeted drugs are currently undergoing clinical trials.
SUMMARY
Numerous recent studies focus on the role of FGFR3 in different urothelial carcinoma subtypes and its potential clinical application as noninvasive biomarker, as well as therapeutic target.
目的综述
成纤维细胞生长因子受体（FGFR）信号通路，特别是 FGFR3 诱导的信号通路，是膀胱癌发病机制中的关键因素，因此在过去几十年中得到了广泛研究。在这篇综述中，我们总结了过去两年中最相关的发现。
最新发现
最近的研究支持 FGFR3 介导与低恶性潜能相关的尿路上皮癌发生途径的概念。FGFR3 可能是诊断和预测复发、进展或治疗反应的高度准确的生物标志物。泛 FGFR 抑制剂 erdafitinib 最近被批准用于膀胱癌，而其他几种 FGFR 靶向药物目前正在进行临床试验。
总结
许多最近的研究集中在 FGFR3 在不同的尿路上皮癌亚型中的作用及其作为非侵入性生物标志物以及治疗靶点的潜在临床应用。
Zotero 插件